Back to Trades
Total Value
$NaN
Filing Date
Mar 18, 2026
1 transactions
Trade Summary
On Mar 18, 2026, Muken Ross, President, reported $NaN of SOPHiA GENETICS SA (SOPH) across 1 transactions. The filing covers company securities and reflects balanced net activity of $NaN. Insider transactions are sourced from SEC Form 4 disclosures and should be reviewed alongside company fundamentals and the insider's broader trading history.
Company Information
- Company Name
- SOPHiA GENETICS SA
- Ticker Symbol
- SOPH
- CIK
- 0001840706
Insider Information
- Name
- Muken Ross
- Role
- President
- Location
- BOSTON, MA
Filing Details
- Filing Date
- Mar 18, 2026
- Transaction Date
- Mar 18, 2026
- Accession Number
- 0001840706-26-000043
- Form Type
- 3
Want live alerts when Muken Ross trades again?
Download Insider Trades to track SOPH, follow insiders, and get mobile alerts when new SEC Form 4 filings are published.
Footnotes
- (F1)Shares are held by the Ross Muken 2026 Irrevocable Trust. The Reporting Person's spouse is the beneficiary. The trust is irrevocable and the Reporting Person does not have the power to direct the trustees with respect to the voting or disposition of the securities held by the trust. A friend of the Reporting Person and an independent attorney serve as co-trustees. The Reporting Person retains the power to remove and replace the trustees. The Reporting Person disclaims beneficial ownership of these securities except to the extent of any pecuniary interest therein.
- (F2)Includes 249,158 ordinary shares issuable upon settlement of five restricted stock unit ("RSU") grants. Each RSU represents a contingent right to receive one ordinary share of the Issuer, vesting subject to the Reporting Person's continued service with the Issuer, as follows: (i) 6,196 ordinary shares from a May 18, 2022 grant vesting in equal monthly installments through May 18, 2026; (ii) 68,100 ordinary shares from an April 3, 2023 grant vesting in equal quarterly installments through April 3, 2027; (iii) 64,053 ordinary shares from an April 2, 2024 grant vesting in equal quarterly installments through April 2, 2028; (iv) 14,358 ordinary shares from a December 18, 2024 grant vesting in equal quarterly installments through December 18, 2028; and (v) 96,451 ordinary shares from an April 2, 2025 grant, with 50% vesting on April 2, 2026 and the remainder vesting in equal quarterly installments through April 2, 2027.
- (F3)The share options are fully vested and exercisable.
- (F4)The share option vests and becomes exercisable as to 25% of the ordinary shares on April 3, 2024, and then in equal monthly installments through April 3, 2027.
- (F5)The share option vests and becomes exercisable as to 25% of the ordinary shares on April 2, 2025, and then in equal monthly installments through April 2, 2028.
- (F6)The share option vests and becomes exercisable as to 25% of the ordinary shares on December 18, 2025, and then in equal monthly installments through December 18, 2028.
- (F7)The share option vests and becomes exercisable as to 50% of the ordinary shares on April 2, 2026, and then in equal monthly installments through April 2, 2027.